Table 3.

Renal outcomes and death by ACE/ID genotype in the losartan group compared with the placebo group

Losartan, n/N (%)Placebo, n/N (%)Adjusteda Risk Reduction Losartan vs Placebo(95% CI)Pb
Composite endpoint of doubling of serum creatinine, ESRD, or death
II72/170 (42.4)85/200 (42.5)5.8 (−23.3 to 28.0)0.215
ID155/352 (44.0)151/317 (47.6)17.6 (3.8 to 29.4)
DD81/189 (42.9)106/207 (51.2)27.9 (7.0 to 44.1)
ESRD or death
II58/170 (34.1)67/200 (33.5)7.5 (−24.6 to 31.4)0.149
ID120/352 (34.1)132/317 (41.6)22.3 (7.6 to 34.6)
DD60/189 (31.7)87/207 (42.0)34.6 (13.0 to 50.9)
Doubling of serum creatinine
II40/170 (23.5)54/200 (27.0)10.2 (−29.2 to 37.6)0.250
ID77/352 (21.9)71/317 (22.4)24.3 (6.2 to 38.9)
DD38/189 (20.1)60/207 (29.0)36.2 (8.5 to 55.5)
ESRD
II39/170 (22.9)42/200 (21.0)3.1 (−41.0 to 33.3)0.032
ID67/352 (19.0)84/317 (26.5)30.5 (13.0 to 44.4)
DD30/189 (15.9)56/207 (27.1)50.1 (27.1 to 65.8)
Death
II28/170 (16.5)37/200 (18.5)0.4 (−49.2 to 33.5)0.927
ID82/352 (23.3)64/317 (20.2)1.8 (−23.4 to 21.9)
DD38/189 (20.1)49/207 (23.7)3.2 (−39.9 to 33.1)
Doubling of serum creatinine or ESRD
II56/170 (32.9)65/200 (32.5)2.3 (−33.7 to 28.6)0.084
ID105/352 (29.8)104/317 (32.8)21.6 (5.8 to 34.8)
DD52/189 (27.5)79/207 (38.2)37.1 (14.4 to 53.8)
  • CI, confidence interval; ESRD, end-stage renal disease; n/N, number of patients who had an event/total number of patients.

  • a Adjusted with terms including treatment (losartan or placebo), geographic region, genotype, and the treatment × genotype interaction.

  • b P value for treatment × genotype interaction (i.e., comparison of the losartan treatment effect between the 3 genotype groups).